HNMI Q4 Operating Profit Up 23% to $12.8M, Revenue $102.5M

Hanmi Science (HNMI) reported Q4 operating profit of $12.8 million, up 23% from $10.4 million in the same period of 2025, on revenue of $102.5 million, a 12% increase from $91.5 million in Q4 2025. The improvement followed strong sales of diagnostic reagents and consumables, with the company attributing the margin expansion to higher unit prices and improved production efficiency. The results reflect continued momentum in the biotech supply chain amid steady demand from hospitals and diagnostic labs.